SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife is capturing significant community attention through its multichain presence and unique deflationary burn mechanism. Supporters are actively driving a cult-like narrative, encouraging others to increase their holdings and framing the project as a standout meme coin with long-term potential.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is generating intense social media hype as traders debate whether its rapid price volatility signals a sustainable breakout or a speculative bubble. The community is actively comparing it to past viral token surges while speculating on potential high-profile endorsements and its role in a broader shift toward community-takeover crypto projects.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as shareholders voice intense dissatisfaction with the company's $18-per-share sale to Garda Therapeutics, arguing the price significantly undervalues their core growth assets. Investors are actively debating the lack of transparency in the strategic review process, the removal of potential long-term upside in Rolvedon and Sympazan, and the perceived conflict of interest regarding executive compensation.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a focal point for the crypto community, driven by excitement over its high-speed blockchain capabilities, growing DeFi and memecoin ecosystems, and anticipation surrounding potential ETF inflows. While some community members remain wary of volatility and ongoing market fluctuations, bulls are actively focused on staking and dip-buying as they eye long-term adoption trends within the Solana network.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors weigh its long-term potential in the decentralized finance sector, with many discussing its fundamental value, tokenomics, and recent protocol upgrades. While some community members remain focused on long-term accumulation and the potential for a larger breakout, others are debating the impact of ongoing market volatility and the competitive landscape of lending protocols.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is currently locked in a consolidation phase near key resistance levels, with the community actively debating whether the asset will break through to establish new highs or undergo a deeper technical correction. Traders are heavily focused on critical support zones and the interplay between institutional ETF flows and broader market liquidity.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is experiencing heightened investor frustration and debate, primarily driven by concerns over ongoing token dilution, stagnant price action relative to broader market gains, and leadership sentiment. While some community members remain aggressively bullish on long-term accumulation and the potential impact of proposed ETFs, others are pivoting toward emerging meme coins on the Cronos chain or exiting entirely, citing a lack of confidence in the platform's strategic direction.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors gear up for the upcoming BlueBird 7 launch on the New Glenn rocket, viewing the event as a critical milestone for validating the company's commercial network capabilities. The community is actively debating the significance of the launch while navigating recent volatility and news of institutional share sales, with many shareholders maintaining a bullish outlook on the company's long-term potential for global cellular connectivity.

Dow Jones Industrial Average

Dow Jones Industrial Index

The Dow Jones Industrial Index is facing heightened volatility and intense scrutiny as investors grapple with shifting macroeconomic data, geopolitical tensions in the Middle East, and skepticism over recent political commentary regarding market performance. Community discussion remains heavily polarized, with many traders debating the sustainability of current price levels amid concerns of inflation, weakening economic indicators, and the potential impact of ongoing global conflicts on institutional capital flows.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is currently a major point of discussion as the community rallies around its status as the leading memecoin on the Bitcoin network, emphasizing its decentralized structure and fixed supply as key advantages. Supporters are actively encouraging long-term accumulation, framing recent price consolidation as a strategic entry point before the next anticipated cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

Equity

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.


<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

<ul class="summary-bullets"><li>The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.</li><li>Yartemlea is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy.</li><li>The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.</li></ul> Shares of Omeros Corp. (OMER) are on track to close their best week since late December, if gains hold, after the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.Yartemlea is the first and only approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The condition can hit people after a stem cell or bone marrow transplant and is a rare, severe, and potentially fatal complication where microscopic blood clots form in small vessels, damaging organs, particularly the kidneys and brain.The company said on Thursday that the J-code will become effective on July 1.<h2 class="st-heading-2">What Is The J-Code?</h2>A J-code is an official “billing sticker” that doctors and hospitals use when they give a patient non-orally administered medications, such as injections, infusions, and chemotherapy. A permanent J-code is designed to simplify billing and speed up reimbursement for a treatment when used by patients covered by Medicare, Medicaid and most commercial insurance plans.Omeros said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.“For patients with TA-TMA, access to effective treatment without unnecessary delay is critical,” said CEO Gregory A. Demopulos. “The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers.”The U.S. Food and Drug Administration approved Yartemlea in December for the treatment of TA-TMA in adults and children aged two years and older. The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user highlighted the company’s partnership with Danish drugmaker Novo Nordisk (NVO).<stembedurl>https://www.stocktwits.com/resq1/message/650620063</stembedurl>Omeros and Novo entered into a definitive asset purchase and license agreement in October for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders. Under the deal, Omeros is eligible to receive up to $2.1 billion, including milestone payments.Yet another Stocktwits user applauded the J-code as “actually huge” and voiced optimism for it driving commercial acceleration of Yartemlea.<stembedurl>https://www.stocktwits.com/mjk49/message/650580855</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained about 97% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-week-on-over-2-years/cZJUwtIRIUf">PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment

Omeros said that the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.

<ul class="summary-bullets"><li>UBS stated in its note that the competitive intensity in the battery energy storage systems space is increasing.</li><li>The firm cited the Trump administration’s tax policy, which incentivizes auto manufacturers to shift from battery production for electric vehicles to utility-scale BESS.</li><li>UBS expects an oversupply of BESS starting in 2027, which will push costs down and increase pressure on Fluence Energy’s margins.</li></ul>Shares of Fluence Energy Inc. (FLNC) could be in for further decline after falling more than 24% year to date, with UBS analysts flagging concerns about battery oversupply.According to TheFly, UBS downgraded Fluence Energy to ‘Sell’ from ‘Neutral’ and lowered its price target by 64% to $8 from $22. The firm’s new price target implies a 43% downside from Fluence Energy’s Thursday closing price.<a href="https://stocktwits.com/symbol/FLNC">Fluence Energy shares</a> were down more than 9% in Friday’s pre-market trade.<h2 class="st-heading-2">UBS Highlights Increasing Competitive Intensity</h2>UBS stated in its note that competitive intensity in the battery energy storage systems (BESS) space is increasing, citing the Trump administration’s tax policy that incentivizes auto manufacturers to shift production from batteries for electric vehicles to utility-scale BESS.The firm expects an oversupply of BESS starting in 2027, which will push costs down and thereby increase pressure on Fluence’s margins. UBS added that the market currently “significantly underappreciates” the manufacturing capacity additions of BESS due to U.S. tax policies for the sector.Analysts at Goldman Sachs also trimmed their price target for Fluence Energy to $20 from $28 while keeping a ‘Buy’ rating on the stock. The firm stated that it expects the first quarter (Q1) to be a “noisy” one for the company.Barclays analysts noted that while Fluence Energy has resolved the tax credit risk after its supplier retained compliance with the Foreign Entity of Concern rules, the Middle East shipping disruptions due to the Iran war could result in Fluence missing second-quarter (Q2) sales estimates. Barclays lowered its price target for Fluence Energy to $16 from $20, while maintaining an ‘Equal Weight’ rating.Fluence Energy reaffirmed earlier this month the continued availability of its U.S.-manufactured products that qualify for tax incentives under the One Big Beautiful Bill Act.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/FLNC">Fluence Energy</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/FLNC">FLNC stock</a> is down 24% year-to-date, but up 312% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 46% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/envb-stock-on-track-worst-decline-10-weeks-enveric-private-placement/cZJUl4KRIx0">ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Fluence Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FLNC Stock Has Dropped 24% This Year — And More Pain May Be Coming Due To Trump Administration’s Tax Policies

UBS downgraded Fluence Energy to ‘Sell’ from ‘Neutral’ and lowered its price target by 64% to $8 from $22, which implies a 43% downside from the closing price on Thursday.

<ul class="summary-bullets"><li>Earlier this week, Credo announced an acquisition of DustPhotonics, a developer of Silicon Photonics Photonic Integrated Circuit technology for optical transceivers.&nbsp;</li><li>Goldman Sachs analyst James Schneider noted Credo's acquisition of DustPhotonics, saying the deal would accelerate its expansion into optical networking.&nbsp;</li><li>According to data from Koyfin, analysts covering CRDO stock have a 12-month average price target of $204.59, indicating an upside potential of about 28.7%.</li></ul>Shares of Credo Technology Group Holding (CRDO) have rallied more than 46% in the past 5 days, gaining attention from investors and Wall Street analysts alike.The company has been riding the wave of optimism over its <a href="https://stocktwits.com/news-articles/markets/equity/crdo-stock-soars-post-market-on-dustphotonics-acquisition/cZJ8QyZRIuy">acquisition of DustPhotonics</a>, a developer of Silicon Photonics Photonic Integrated Circuit (SiPho PIC) technology for optical transceivers, announced earlier this week.Following the news, Jefferies raised its price target on Credo to $225 from $175, while maintaining a ‘Buy’ rating on the stock, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/analyst-ratings/jefferies-raises-credo-technology-stock-price-target-on-optics-growth-93CH-4619456">according</a> to Investing.com. The updated target represents an upside potential of about 41.6% from the last close.Earlier in the day, Goldman Sachs also raised the price target on Credo to $170 from $150 and kept a ‘Buy’ rating on its shares, as per TheFly.<h2 class="st-heading-2">Street Consensus</h2>Jefferies said that it increased its estimates after Credo’s acquisition of DustPhotonics and the company’s guidance for more than $500 million in total Optics revenue for fiscal 2027. The analyst expects Credo’s Optics business in FY27 to generate approximately $125 million in Optical DSP revenue, more than $300 million in ZF Optics, and approximately $75 million in standalone PIC revenue.Goldman Sachs analyst James Schneider also noted Credo's acquisition of DustPhotonics, saying that the deal would accelerate its expansion into optical networking and strengthen confidence in its diversification beyond copper-based active electrical cables, with improved visibility toward its $500 million optical revenue target by FY27, the analyst said.Meanwhile, Bank of America raised its price target on the company to $210 from $160 and kept a ‘Buy’ rating on the shares after the acquisition. Rosenblatt analyst Mike Genovese also raised the firm's price target on Credo to $175 from $125 and kept a ‘Neutral’ rating on the shares.According to data from Koyfin, 16 out of 17 analysts covering CRDO stock have a ‘Buy’ or higher rating on it, with a 12-month average price target of $204.59, indicating an upside potential of about 28.7%.<h2 class="st-heading-2">Stronger AI Connectivity</h2>Credo’s acquisition of DustPhotonics is aimed at strengthening its optical interconnect roadmap and expanding its footprint in the global optical market. DustPhotonics’ silicon photonics technology will enhance performance, lower costs, and improve reliability for AI data centers, while boosting Credo’s ZeroFlap platform and reducing supply dependencies, the company said.Credo also said that it sees this as a key inflection point, expecting its optical business to surpass $500 million in revenue by FY27, supported by growing hyperscale AI demand. CEO William Brennan called the deal a defining step toward leading AI connectivity.<h2 class="st-heading-2">Retail Reaction</h2>On Stocktwits, retail sentiment around CRDO stock was in the ‘extremely bullish’ territory amid ‘extremely high’ message volumes at the time of writing. Retail chatter around the stock has increased 79% in the past week.While <a href="https://stocktwits.com/symbol/CRDO">CRDO shares</a> closed down 5.6% on Thursday, they have rallied more than 321% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Credo Technology logo is displayed on a smartphone screen

CRDO Stock Has Surged 46% In The Past 5 Days — Does It Have Room For More Upside?

Jefferies raised its price target on Credo Technology to $225 from $175, indicating an upside potential of about 41.6% from last close. 

<ul class="summary-bullets"><li>Quantum stocks have been on an upswing over the past few trading sessions, with AI bellwether Nvidia’s Ising launch earlier this week reigniting momentum in the sector.</li><li>D-Wave Quantum CEO Alan Baratz told Yahoo Finance during an interview on Thursday that the company has already crossed the “ChatGPT moment” in quantum computing.</li><li>He credited this to a method known as quantum annealing, which uses quantum physics to find the problem's low-energy states.</li></ul>Shares of D-Wave Quantum Inc. (QBTS) gained nearly 8% in Thursday’s pre-market trade&nbsp;and are on track to cross the 100-day moving average for the first time since January this year.If D-Wave shares continue the pre-market momentum through the day, this would be the fifth consecutive day of gains for the company’s stock.<a href="https://stocktwits.com/symbol/NVDA">D-Wave shares</a> have surged more than 43% over the previous five trading sessions.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_16_at_7_01_31_AM_png_ddff2f3957.webp" alt="Screenshot 2026-04-16 at 7.01.31 AM.png" width="3326" height="1822"><figcaption>Source: TradingView</figcaption></figure><h2 class="st-heading-2">What Is Fueling The QBTS Rally?</h2>Quantum stocks have been on an upswing over the past few trading sessions, with AI bellwether Nvidia Corp.’s (NVDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jensen-huang-nvidia-ising-quantum-stocks-qbts-rgti-qubt-soar/cZJqfdwRIvd">Ising launch</a> earlier this week bringing back the momentum in the sector.On the sidelines of the Semafor World Economic Summit, D-Wave Quantum CEO Alan Baratz told Yahoo Finance&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/news/d-wave-ceo-says-quantum-computing-is-already-past-its-chatgpt-moment-214253705.html">during</a> an interview on Thursday that the company has crossed the “ChatGPT moment” for quantum computing already.Baratz credited this to a method known as quantum annealing, which uses quantum physics to find a problem's low-energy states. This technique is then used to arrive at the optimal or a near-optimal combination of elements. D-Wave’s computers are the most famous example of quantum annealers.D-Wave’s technology is currently being used in cellular networks and pharmaceutical supply chains.“For annealing, we've hit that point. For gate model systems. We're still a few years away from it,” Baratz added, while noting that it needs some more engineering.<h2 class="st-heading-2">Why Is This Important?</h2>D-Wave’s approach addresses the critical power-efficiency challenge currently facing the AI industry.Baratz stated in the interview that D-Wave’s quantum computers draw only 10 kilowatts to solve a problem and that the company’s technology can provide a solution within minutes, while a massive GPU cluster would require the “world’s power” and millions of years to achieve the same.On Tuesday, while announcing Ising, Nvidia CEO Jensen Huang stated that AI is essential to making quantum computing practical, as Nvidia’s new open AI model aims to help enterprises turn quantum processors into large-scale, reliable computers.“With Ising, AI becomes the control plane — the operating system of quantum machines — transforming fragile qubits to scalable and reliable quantum-GPU systems,” Huang said.This comes at a time when AI is expected to drive a surge in global electricity demand. According to an April 2025&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.iea.org/news/ai-is-set-to-drive-surging-electricity-demand-from-data-centres-while-offering-the-potential-to-transform-how-the-energy-sector-works">report</a> by the International Energy Agency, electricity demand from data centers worldwide is projected to more than double by 2030, to 945 terawatt-hours.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QBTS">QBTS</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user stated that quantum technology and nuclear are the future and hope of humanity.<stembedurl>https://stocktwits.com/QuantumKVY/message/650438448</stembedurl><a href="https://stocktwits.com/symbol/QBTS">QBTS stock</a> is down 20% year-to-date, but up 201% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 44% over the past 12 months, while the Vanguard Total Stock Market Index Fund ETF (VTI) is up 31%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-myse-stock-soaring-today/cZJvidNRID3">MYSE Stock Is Up More Than 200% Pre-Market Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, D-Wave Systems Inc. logo of a Canadian quantum computing company is seen on a smartphone screen. 

QBTS Stock On Track To Cross 100-DMA For First Time Since January After Gaining 43% In 5 Days — What Is Powering The Surge?

If D-Wave shares continue the pre-market momentum through the day, this would be the fifth consecutive day of gains for the stock.

Peak of Iran War Priced-In? Low-P/E High Momentum ETFs in Focus 

Markets may have priced in peak Iran war fears. With volatility easing, low P/E, high-momentum ETFs are emerging as smart bets for near-term gains.

<ul class="summary-bullets"><li>Credo said that it will pay $750 million in cash upfront and about 0.92 million shares of Credo common stock for DustPhotonics’ acquisition.</li><li>The transaction is expected to close in the second quarter of calendar year 2026.&nbsp;</li><li>Prior to the deal announcement, Jefferies initiated coverage of Credo Technology with a ‘Buy’ rating and $175 price target on Monday.</li></ul>Shares of Credo Technology Group Holding (CRDO) surged more than 10% in Monday’s extended trading hours after the company announced the acquisition of DustPhotonics, a developer of Silicon Photonics Photonic Integrated Circuit (SiPho PIC) technology for optical transceivers.Credo said that it will pay $750 million in cash upfront and nearly 1 million shares of Credo common stock for DustPhotonics’ purchase. Credo said that it may also pay incremental contingent consideration of up to approximately 3.21 million shares in addition, based on the achievement of certain financial milestones.The semiconductor company said that the deal will be accretive to adjusted earnings per share in its fiscal 2027.The transaction is expected to close in the second quarter of calendar year 2026.<h2 class="st-heading-2">Deal Rationale</h2>The acquisition will accelerate Credo's optical interconnect roadmap and expand its served addressable market in the global optical industry. DustPhotonics brings advanced silicon photonics (SiPho PICs) enabling higher speeds, lower costs, and improved reliability for AI data centers, the company said.Integrating these capabilities will boost Credo’s ZeroFlap platform, reduce supply dependencies, and accelerate innovation.Credo said that it believes it has reached an inflection point in its optical business, and the acquisition of DustPhotonics will help its optical portfolio generate more than $500 million in revenue in fiscal 2027, driven by strong customer traction and expanding adoption across hyperscale AI deployments, the company said.William Brennan, Chairman, and CEO, said the deal was “a defining step in Credo’s strategy to lead across the full spectrum of AI connectivity.”<h2 class="st-heading-2">Analyst Confidence</h2>Prior to the deal announcement, Jefferies initiated coverage of Credo Technology with a ‘Buy’ rating and $175 price target on Monday. The analyst said that Credo offered a "meaningful opportunity” to invest in a premium growth company that was trading at a significantly discounted valuation.The analyst said that it sees a "significant disconnect" between the market's perception of Credo's AI opportunity over the next several years relative to its actual opportunity.As per data from Koyfin, analysts have a 12-month average price target of $197.94 on the company’s shares, representing an upside potential of 47.32% from the last close.<h2 class="st-heading-2">Retail Reaction</h2>On Stocktwits, retail sentiment around CRDO shares jumped from ‘neutral’ to ‘bullish’ over the past day, while message volumes surged from ‘low’ to ‘high’ levels.One bullish user called the deal a “Massive Acquisition Move,” while highlighting the key takeaways.<stembedurl>https://stocktwits.com/BottomFisher_/message/650164177</stembedurl>Another user predicted the stock would go back to $200 levels, where it was trading at around December 2025.<stembedurl>https://stocktwits.com/m_23nyc/message/650164814</stembedurl><a href="https://stocktwits.com/symbol/CRDO">CRDO stock</a> has rallied more than 243% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRDO Stock Soars Post-Market On DustPhotonics Acquisition: Retail Eyes Surge To Over $200 

Credo Technology said that it believes it has reached an inflection point in its optical business, and the DustPhotonics deal will help its optical portfolio generate more than $500 million in revenue in fiscal 2027.

<ul class="summary-bullets"><li>Spyre is looking forward to developing the drug as a single treatment, as well as in combination with its investigational antibodies SPY002 or SPY003.</li><li>TD Cowen says Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001.</li><li>Leerink continues to view the trial data as a best-case outcome for SPY00, one which derisks both its potential as a monotherapy and backbone in future combination regimens.</li></ul>Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data, with several noting the company’s experimental drug’s potential against Takeda’s Entyvio.The stock marked its highest single-day gain on Monday since June 2023.Earlier in the day, Spyre announced positive data from part A of its phase 2 trial of SPY001 in the treatment of moderate-to-severely active ulcerative colitis. The company said that the trial met its primary endpoint of statistically significant reduction in disease activity.The drug was further well tolerated though six subjects experienced treatment-emergent adverse events, including a serious event which the company deems as not related to the drug.Spyre is looking forward to developing the drug as a single treatment as well as in combination with its investigational antibodies SPY002 or SPY003.<h2 class="st-heading-2">Analyst Take Away</h2>TD Cowen said Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001. The firm has a ‘Buy’ rating on Spyre.Wedbush analyst David Nierengarten, meanwhile, raised the firm's price target on Spyre to $80 from $65 and kept an ‘Outperform’ rating on the shares. Spyre's SPY001 monotherapy surpassed historical benchmarks for Takeda's (TAK) Entyvio with 40% clinical remission and 51% endoscopic improvement, yielding an anticipated upside scenario, the analyst told investors in a research note.Leerink, which also has an ‘Outperform’ rating on the stock, raised the firm's price target on Spyre Therapeutics to $106 from $49. Leerink continues to view the trial data as a best-case outcome for SPY001, one which derisks both its potential as a monotherapy and backbone in future combination regimens. The target change reflects the firm's increased conviction and higher probability of success for SPY001 opportunities in UC and Crohn's disease, it said.Overall, the firm believes these "striking initial” study results represent best case data for SPY001, suggesting positively differentiated efficacy vs. Entyvio across a broad range of objective and symptomatic measures. The data position SPY001 as a leading agent in this multi-billion-dollar class, argues Leerink.Stoked by the data, BTIG analyst Julian Harrison also raised the firm's price target on Spyre to $98 from $70, and kept a ‘Buy’ rating on the shares while raising the firm's view of the odds of success for SPY001 combos in UC to 80% following the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SYRE stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SYRE">SYRE stock</a> has gained nearly 400% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eras-stock-slumps-against-rvmd-rally-analyst-stays-bullish/cZJ8IHGRIuH">ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data

Earlier in the day, Spyre said that part of its phase 2 ulcerative colitis trial met its primary endpoint of statistically significant reduction in disease activity.


Could Investing $10,000 in IWM Make You a Millionaire?

Key PointsThe iShares Russell 2000 ETF has delivered average annual returns of 8.06% for almost 26 years...

iShares Trust - iShares Russell 2000 ETF

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

iShares Russell 2000 ETF

A growing crowd of retail investors is expressing disbelief at the market's inability to see a red day or significant pullback.

Discussions are dominated by the impact of geopolitical tension and ceasefire headlines on market pumps and asset pricing.

Retail traders are increasingly pointing to computer algorithms as the primary driver behind the consistent and relentless daily market push.

Persistent gains are putting massive pressure on bears, leading to aggressive short covering and warnings to avoid betting against the momentum.

Current Price	$275.78
Prev Close	$269.95
Open	$273.74
Dividend Yield	N/A
50-Day Moving Average	$257.19
Beta	N/A
Avg. Volume	54.82M
PE Ratio	N/A

52-Week High	$277.63
52-Week Low	$180.77
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF